BACKGROUND: Long-term survival for patients with AIDS-related diffuse large B-cell lymphoma (DLBCL) is feasible in settings with available combination antiretroviral therapy (cART). However, given limited oncology resources, outcomes for AIDS-associated DLBCL in South Africa are unknown. METHODS: We performed a retrospective analysis of survival in patients with newly diagnosed AIDS-related DLBCL treated at a tertiary teaching hospital in Cape Town, South Africa, with cyclophosphamide, doxorubicin, vincristine, and oral prednisone (CHOP) or CHOP-like chemotherapy (January 2004 until December 2010). HIV-related and lymphoma-related prognostic factors were evaluated. RESULTS: Thirty-six patients evaluated; median age 37.3 years, 52.8% men, and 61.1% black South Africans. Median CD4 count 184 cells per microliter (in 27.8% this was <100 cells/μL), 80% high risk according to the age-adjusted International Prognostic Index. Concurrent Mycobacterium tuberculosis in 25%. Two-year overall survival (OS) was 40.5% (median OS 10.5 months, 95% confidence interval: 6.5 to 31.8). Eastern Cooperative Oncology Group performance status of 2 or more (25.4% vs 50.0%, P = 0.01) and poor response to cART (18.0% vs 53.9%, P = 0.03) predicted inferior 2-year OS. No difference in 2-year OS was demonstrated in patients coinfected with M. tuberculosis (P = 0.87). CONCLUSIONS: Two-year OS for patients with AIDS-related DLBCL treated with CHOP like regimens and cART is comparable to that seen in the United States and Europe. Important factors effecting OS in AIDS-related DLBCL in South Africa include performance status at presentation and response to cART. Patients with comorbid M. tuberculosis or hepatitis B seropositivity seem to tolerate CHOP in our setting. Additional improvements in outcomes are likely possible.
BACKGROUND: Long-term survival for patients with AIDS-related diffuse large B-cell lymphoma (DLBCL) is feasible in settings with available combination antiretroviral therapy (cART). However, given limited oncology resources, outcomes for AIDS-associated DLBCL in South Africa are unknown. METHODS: We performed a retrospective analysis of survival in patients with newly diagnosed AIDS-related DLBCL treated at a tertiary teaching hospital in Cape Town, South Africa, with cyclophosphamide, doxorubicin, vincristine, and oral prednisone (CHOP) or CHOP-like chemotherapy (January 2004 until December 2010). HIV-related and lymphoma-related prognostic factors were evaluated. RESULTS: Thirty-six patients evaluated; median age 37.3 years, 52.8% men, and 61.1% black South Africans. Median CD4 count 184 cells per microliter (in 27.8% this was <100 cells/μL), 80% high risk according to the age-adjusted International Prognostic Index. Concurrent Mycobacterium tuberculosis in 25%. Two-year overall survival (OS) was 40.5% (median OS 10.5 months, 95% confidence interval: 6.5 to 31.8). Eastern Cooperative Oncology Group performance status of 2 or more (25.4% vs 50.0%, P = 0.01) and poor response to cART (18.0% vs 53.9%, P = 0.03) predicted inferior 2-year OS. No difference in 2-year OS was demonstrated in patients coinfected with M. tuberculosis (P = 0.87). CONCLUSIONS: Two-year OS for patients with AIDS-related DLBCL treated with CHOP like regimens and cART is comparable to that seen in the United States and Europe. Important factors effecting OS in AIDS-related DLBCL in South Africa include performance status at presentation and response to cART. Patients with comorbid M. tuberculosis or hepatitis B seropositivity seem to tolerate CHOP in our setting. Additional improvements in outcomes are likely possible.
Authors: R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller Journal: N Engl J Med Date: 1993-04-08 Impact factor: 91.245
Authors: Moses H Bateganya; Jeffrey Stanaway; Paula E Brentlinger; Amalia S Magaret; Anna Wald; Jackson Orem; Corey Casper Journal: J Acquir Immune Defic Syndr Date: 2011-04 Impact factor: 3.731
Authors: Joseph A Sparano; Jeannette Y Lee; Lawrence D Kaplan; Alexandra M Levine; Juan Carlos Ramos; Richard F Ambinder; William Wachsman; David Aboulafia; Ariela Noy; David H Henry; Jamie Von Roenn; Bruce J Dezube; Scot C Remick; Manisha H Shah; Lawrence Leichman; Lee Ratner; Ethel Cesarman; Amy Chadburn; Ronald Mitsuyasu Journal: Blood Date: 2009-12-18 Impact factor: 22.113
Authors: E A Abayomi; A Somers; R Grewal; G Sissolak; F Bassa; D Maartens; P Jacobs; C Stefan; L W Ayers Journal: Transfus Apher Sci Date: 2011-04 Impact factor: 1.764
Authors: Walter O Mwanda; Jackson Orem; Pingfu Fu; Cecilia Banura; Joweria Kakembo; Caren Auma Onyango; Anne Ness; Sherrie Reynolds; John L Johnson; Vivek Subbiah; Jacob Bako; Henry Wabinga; Fatuma K Abdallah; Howard J Meyerson; Christopher C Whalen; Michael M Lederman; Jodi Black; Leona W Ayers; Edward Katongole-Mbidde; Scot C Remick Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Christopher C Stanley; Kate D Westmoreland; Brett J Heimlich; Nader K El-Mallawany; Peter Wasswa; Idah Mtete; Mercy Butia; Salama Itimu; Mary Chasela; Mary Mtunda; Mary Chikasema; Victor Makwakwa; Bongani Kaimila; Edwards Kasonkanji; Fred Chimzimu; Coxcilly Kampani; Bal M Dhungel; Robert Krysiak; Nathan D Montgomery; Yuri Fedoriw; Nora E Rosenberg; N George Liomba; Satish Gopal Journal: Br J Haematol Date: 2016-02-23 Impact factor: 6.998
Authors: Matthew S Painschab; Edwards Kasonkanji; Takondwa Zuze; Bongani Kaimila; Tamiwe Tomoka; Richard Nyasosela; Ruth Nyirenda; Bal M Dhungel; Maurice Mulenga; Maria Chikasema; Blessings Tewete; Asekanadziwa Mtangwanika; Sarah Chiyoyola; Wilberforce Mhango; Fred Chimzimu; Coxcilly Kampani; Robert Krysiak; Thomas C Shea; Nathan D Montgomery; Yuri Fedoriw; Satish Gopal Journal: Br J Haematol Date: 2018-11-18 Impact factor: 6.998
Authors: Tamiwe Tomoka; Nathan D Montgomery; Eric Powers; Bal Mukunda Dhungel; Elizabeth A Morgan; Maurice Mulenga; Satish Gopal; Yuri Fedoriw Journal: Clin Lab Med Date: 2017-12-13 Impact factor: 1.935
Authors: Gerhard Sissolak; Matthew Seftel; Thomas S Uldrick; Tonya M Esterhuizen; Nooroudien Mohamed; Danie Kotze Journal: J Glob Oncol Date: 2016-08-31
Authors: Olugbenga Akindele Silas; Chad J Achenbach; Lifang Hou; Robert L Murphy; Julie O Egesie; Solomon A Sagay; Oche O Agbaji; Patricia E Agaba; Jonah Musa; Agabus N Manasseh; Ezra D Jatau; Ayuba M Dauda; Maxwell O Akanbi; Barnabas M Mandong Journal: Infect Agent Cancer Date: 2017-06-05 Impact factor: 2.965
Authors: Maudy C P Manyau; Tinashe Mudzviti; Simbarashe Rusakaniko; Elson T Mberi; Charles C Maponga; Gene D Morse Journal: PLoS One Date: 2020-09-17 Impact factor: 3.240
Authors: Satish Gopal; Yuri Fedoriw; Bongani Kaimila; Nathan D Montgomery; Edwards Kasonkanji; Agnes Moses; Richard Nyasosela; Suzgo Mzumara; Carlos Varela; Maria Chikasema; Victor Makwakwa; Salama Itimu; Tamiwe Tomoka; Steve Kamiza; Bal M Dhungel; Fred Chimzimu; Coxcilly Kampani; Robert Krysiak; Kristy L Richards; Thomas C Shea; N George Liomba Journal: PLoS One Date: 2016-03-02 Impact factor: 3.240